Vectors Research Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
– Sell
-19
Closed -$1K – 497
2022
Q2
$1K Hold
19
– – ﹤0.01% 498
2022
Q1
$2K Hold
19
– – ﹤0.01% 440
2021
Q4
$2K Hold
19
– – ﹤0.01% 565
2021
Q3
$2K Buy
+19
New +$2.45K ﹤0.01% 461

Other funds holding XBI

Vectors Research Management's XBI Position: Q3 2022 in Review

Vectors Research Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2022, closing a stake of 19 shares — an estimated $1K sold.

Vectors Research Management first reported a position in XBI in Q3 2021 and held it in 4 quarters. The position peaked at $2K in Q1 2022. 703 funds tracked by Wall St. Rank hold XBI as of Q3 2022.

  • Vectors Research Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2022 after selling out during the quarter.
  • Vectors Research Management sold 19 State Street SPDR S&P Biotech ETF shares in Q3 2022, an estimated $1K.
  • Vectors Research Management first reported a position in State Street SPDR S&P Biotech ETF in Q3 2021 and held it in 4 quarters.
  • Vectors Research Management's State Street SPDR S&P Biotech ETF position peaked at $2K in Q1 2022.
  • 703 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2022.

Based on Vectors Research Management's 13F filing for Q3 2022, filed 8 Nov 2022.